drugset
Drugs / TAK-062
last change Nov 2024 re-read 3 minutes ago

TAK-062

Protein / enzyme biologic

Developed for
celiac disease · digestive system disorder
Investigated by
Millennium Pharmaceuticals, Inc. · Takeda

Trials 2

today NCT05353985 · Ph 2 NCT03701555 · Ph 1
20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03701555 Jun 2018 → Jan 2021 digestive system disorder Millennium Pharmaceuticals, Inc. Completed No outcome recorded
Phase 21 trial · 1 missed
Phase 2 NCT05353985 Jun 2022 → Nov 2024 celiac disease Takeda Completed Missed primary

Press releases naming this drug 1 release

DateIssuerRelease
2020-02-26 Takeda Takeda Acquires PvP Biologics Following Results of a Phase 1 Study of TAK-062 (Kuma062) for the Treatment of Celiac Disease takeda.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as TAK-062 “TAK-062 is a novel, computationally designed endopeptidase under development for the treatment of patients with CeD.” PMID 33741317 ↗ Mar 2021
1

NCT05353985 ↗
Modality Protein / enzyme biologic “TAK-062, an Engineered Enzyme to Treat Celiac Disease.” PMID 33741317 ↗ Mar 2021
Route Oral “supporting the development of this novel enzyme as an oral therapeutic for patients with CeD.” PMID 33741317 ↗ Mar 2021